Andrew Combs, EVP, Head of Chemistry at Prelude Therapeutics Inc (PRLD), bought 1,000 shares at $19.00 ($19K) on 2020-09-29, disclosed to the SEC on 2020-09-29.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| PRLD | BUY | 2021-12-15 | $95K | — | Filing → |